Literature DB >> 34213749

Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.

Ann Margaret C Navarroza1, Stephen N Wong2,3.   

Abstract

BACKGROUND: Data on nonalcoholic fatty liver disease (NAFLD) in the Philippines are scarce. We aimed to compare the clinical and biochemical profiles of lean (BMI<23) vs. non-lean (BMI≥23) NAFLD patients.
METHODS: Consecutive patients diagnosed with NAFLD on ultrasound in two outpatient hepatology clinics from February 2007-January 2017 were included. Patients with significant alcohol intake, alternative causes of steatosis, and incomplete data were excluded.
RESULTS: A total of 663 patients (57.9% male) were included. Most patients were non-lean (88.1%) and had an elevated alanine aminotransferase (ALT) (63%). Cirrhosis or hepatocellular carcinoma (HCC) were already present in 8.4% on initial consultation. Concomitant hepatitis B was equally common in patients with and without cirrhosis (20.7% vs. 17.5%; p=0.660) or HCC (17.9% vs. 12.8%; p=0.415). Independent factors associated with HCC/cirrhosis on initial consultation were older age (OR=1.038), low albumin (OR=0.428), high BARD score (BMI, AST/ALT ratio, T2 diabetes mellitus; OR=2.548) and the presence of symptoms (OR=1.808). Compared to lean NAFLD patients, non-lean patients were more likely to be younger (51.5±14.4 vs. 55±14.3; p=0.003), have DM (47.9% vs. 29.1%; p=0.002), hypertension (57.5% vs. 38%; p=0.001), dyslipidemia (73.1% vs. 54.4%; p=0.001) and metabolic syndrome (60.3% vs. 30.4%; p<0.0001), abnormal metabolic parameters (LDL-C, HDL-C, triglycerides, uric acid and FBS), and with elevated ALT (65.2% vs. 46.8%; p=0.002) and AST (41.1±29.6 vs. 35.3±28.3; p=0.008).
CONCLUSIONS: The proportion of lean NAFLD was 11.9%. Although metabolic derangements and its clinical consequences were present in about a third of lean patients, these were still more common in non-lean NAFLD. Cirrhosis or HCC were already present in a significant proportion (8.4%) of NAFLD patients on initial presentation.
© 2021. Indian Society of Gastroenterology.

Entities:  

Keywords:  Body mass index; Cirrhosis of liver; Hepatocellular carcinoma; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; Risk factors

Mesh:

Substances:

Year:  2021        PMID: 34213749     DOI: 10.1007/s12664-021-01184-6

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  1 in total

Review 1.  How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations.

Authors:  Wen-Harn Pan; Wen-Ting Yeh
Journal:  Asia Pac J Clin Nutr       Date:  2008       Impact factor: 1.662

  1 in total
  3 in total

1.  Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease.

Authors:  Anca Trifan; Adrian Rotaru; Remus Stafie; Ermina Stratina; Sebastian Zenovia; Robert Nastasa; Laura Huiban; Tudor Cuciureanu; Cristina Muzîca; Stefan Chiriac; Irina Gîrleanu; Ana-Maria Sîngeap; Catalin Sfarti; Camelia Cojocariu; Carol Stanciu
Journal:  Diagnostics (Basel)       Date:  2022-03-24

2.  Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease: A population based observational study.

Authors:  Xiaoxiao Wang; Xiaohe Li; Rui Jin; Jia Yang; Rui Huang; Lai Wei; Feng Liu; Huiying Rao
Journal:  Hepatol Commun       Date:  2022-05-13

3.  Editorial commentary on Indian Journal of Gastroenterology-July-August 2021.

Authors:  Jimmy K Limdi
Journal:  Indian J Gastroenterol       Date:  2021-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.